ID   451Lu
AC   CVCL_6357
SY   451LU; 451-LU; WM 451-Lu; WM-451Lu; WM-451LU; WM451Lu; WM451; WC00059; LU451; Lu451; EST81
DR   BTO; BTO:0003710
DR   CLO; CLO_0001373
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-2813
DR   BioSample; SAMN03471798
DR   cancercelllines; CVCL_6357
DR   Cell_Model_Passport; SIDM01240
DR   ChEMBL-Cells; CHEMBL4802054
DR   Coriell; WC00059
DR   Cosmic; 686411
DR   Cosmic; 1047656
DR   Cosmic; 1155281
DR   Cosmic; 1155568
DR   Cosmic; 1187587
DR   Cosmic; 1303027
DR   Cosmic; 2163808
DR   Cosmic; 2230114
DR   Cosmic-CLP; 1287706
DR   DepMap; ACH-001002
DR   EGA; EGAS00001000978
DR   ESTDAB; ESTDAB-081
DR   GDSC; 1287706
DR   GEO; GSM156019
DR   GEO; GSM188238
DR   GEO; GSM188268
DR   GEO; GSM188327
DR   GEO; GSM555137
DR   GEO; GSM555187
DR   GEO; GSM952579
DR   GEO; GSM1199178
DR   GEO; GSM1669568
DR   IARC_TP53; 26083
DR   PharmacoDB; 451Lu_17_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_6357
DR   PubChem_Cell_line; CVCL_6357
DR   Rockland; 451Lu-01-0001
DR   Wikidata; Q54603178
RX   PubMed=2068080;
RX   PubMed=2156614;
RX   PubMed=2253310;
RX   PubMed=2918552;
RX   PubMed=8342600;
RX   PubMed=15592718;
RX   PubMed=17260012;
RX   PubMed=18632627;
RX   PubMed=18790768;
RX   PubMed=19340423;
RX   PubMed=21156289;
RX   PubMed=21343389;
RX   PubMed=23285177;
RX   PubMed=23851445;
RX   PubMed=24055054;
RX   PubMed=25056119;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.wistar.org/our-scientists/meenhard-herlyn
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Wistar Institute melanoma cell line collection.
CC   Population: Caucasian.
CC   Characteristics: Metastatic. Established from the lung of a nude mouse after 4 sequential passages of the parent cell line (PubMed=2156614).
CC   Doubling time: 72 hours (PubMed=2253310).
CC   HLA typing: A*24:02,24:02; B*07:02,07:02; DPB1*06:01,06:01; DQB1*06:04,06:04; DRB1*13:01,13:01 (PubMed=15592718).
CC   Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=18632627; PubMed=21156289; PubMed=23851445; Cosmic-CLP; DepMap; Wistar).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=17260012; PubMed=21156289; PubMed=23851445; Cosmic-CLP; DepMap).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0%; Native American=1.32%; East Asian, North=0.06%; East Asian, South=0.98%; South Asian=0.7%; European, North=67.32%; European, South=29.61% (PubMed=30894373).
CC   Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 10->10,13, D5S818: 11,12->12, D7S820: 9,10->10 and FGA: 21->21,25.
CC   Discontinued: ATCC; CRL-2813; true.
CC   Discontinued: Coriell; WC00059; probable.
CC   Derived from site: Metastatic; Arm, skin; UBERON=UBERON_0002427.
ST   Source(s): ATCC; Cosmic-CLP; ESTDAB; PubMed=25056119; Wistar
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 13
ST   D18S51: 10,13
ST   D19S433: 13
ST   D21S11: 28,31.2
ST   D2S1338: 18,19
ST   D3S1358: 18
ST   D5S818: 12
ST   D7S820: 9,10 (ATCC; ESTDAB)
ST   D7S820: 10 (Cosmic-CLP; Wistar)
ST   D8S1179: 13,14
ST   FGA: 21,25
ST   TH01: 9
ST   TPOX: 8,10
ST   vWA: 14,15
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7928 ! WM164
SX   Male
AG   22Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 38
//
RX   PubMed=2068080; DOI=10.1073/pnas.88.14.6028;
RA   Cornil I., Theodorescu D., Man S., Herlyn M., Jambrosic J.A.,
RA   Kerbel R.S.;
RT   "Fibroblast cell interactions with human melanoma cells affect tumor
RT   cell growth as a function of tumor progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6028-6032(1991).
//
RX   PubMed=2156614;
RA   Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A.H., Baird J.,
RA   Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.;
RT   "In vitro properties of human melanoma cells metastatic in nude
RT   mice.";
RL   Cancer Res. 50:2296-2302(1990).
//
RX   PubMed=2253310; DOI=10.1007/BF00046337;
RA   Herlyn M.;
RT   "Human melanoma: development and progression.";
RL   Cancer Metastasis Rev. 9:101-112(1990).
//
RX   PubMed=2918552; DOI=10.1093/jnci/81.6.440;
RA   Iliopoulos D., Ernst C.S., Steplewski Z., Jambrosic J.A., Rodeck U.,
RA   Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.;
RT   "Inhibition of metastases of a human melanoma xenograft by monoclonal
RT   antibody to the GD2/GD3 gangliosides.";
RL   J. Natl. Cancer Inst. 81:440-444(1989).
//
RX   PubMed=8342600;
RA   Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K.,
RA   Herlyn D., Valyi-Nagy I.T., Herlyn M.;
RT   "Growth and invasion of human melanomas in human skin grafted to
RT   immunodeficient mice.";
RL   Am. J. Pathol. 143:528-537(1993).
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235;
RA   Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R.,
RA   Muthusamy V., King A.J., Flaherty K.T., Bosenberg M.W., Herlyn M.,
RA   Nathanson K.L.;
RT   "Identification of a novel subgroup of melanomas with
RT   KIT/cyclin-dependent kinase-4 overexpression.";
RL   Cancer Res. 68:5743-5752(2008).
//
RX   PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431;
RA   Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B.,
RA   Egyhazi Brage S., Hansson J., Wu H., King A.J., Van Belle P.,
RA   Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.;
RT   "Increased cyclin D1 expression can mediate BRAF inhibitor resistance
RT   in BRAF V600E-mutated melanomas.";
RL   Mol. Cancer Ther. 7:2876-2883(2008).
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=21156289; DOI=10.1016/j.ccr.2010.11.023;
RA   Villanueva J., Vultur A., Lee J.T., Somasundaram R.,
RA   Fukunaga-Kalabis M., Cipolla A.K., Wubbenhorst B., Xu X.-W.,
RA   Gimotty P.A., Kee D., Santiago-Walker A.E., Letrero R., D'Andrea K.,
RA   Pushparajan A., Hayden J.E., Dahlman K.B., Laquerre S.G., McArthur G.A.,
RA   Sosman J.A., Nathanson K.L., Herlyn M.;
RT   "Acquired resistance to BRAF inhibitors mediated by a RAF kinase
RT   switch in melanoma can be overcome by cotargeting MEK and
RT   IGF-1R/PI3K.";
RL   Cancer Cell 18:683-695(2010).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958;
RA   Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M.,
RA   Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R.,
RA   Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E.,
RA   Ostrer H., Osman I.;
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=23285177; DOI=10.1371/journal.pone.0052760;
RA   Schayowitz A.B., Bertenshaw G.P., Jeffries E., Schatz T., Cotton J.,
RA   Villanueva J., Herlyn M., Krepler C., Vultur A., Xu W., Yu G.H.,
RA   Schuchter L.M., Clark D.P.;
RT   "Functional profiling of live melanoma samples using a novel automated
RT   platform.";
RL   PLoS ONE 7:E52760-E52760(2012).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=24055054; DOI=10.1016/j.celrep.2013.08.023;
RA   Villanueva J., Infante J.R., Krepler C., Reyes-Uribe P., Samanta M.,
RA   Chen H.-Y., Li B., Swoboda R.K., Wilson M., Vultur A.,
RA   Fukunaga-Kalabis M., Wubbenhorst B., Chen T.Y., Liu Q., Sproesser K.,
RA   DeMarini D.J., Gilmer T.M., Martin A.-M., Marmorstein R., Schultz D.C.,
RA   Speicher D.W., Karakousis G.C., Xu W., Amaravadi R.K., Xu X.-W.,
RA   Schuchter L.M., Herlyn M., Nathanson K.L.;
RT   "Concurrent MEK2 mutation and BRAF amplification confer resistance to
RT   BRAF and MEK inhibitors in melanoma.";
RL   Cell Rep. 4:1090-1099(2013).
//
RX   PubMed=25056119; DOI=10.1158/0008-5472.CAN-14-1232-T;
RA   Watson I.R., Li L.-R., Cabeceiras P.K., Mahdavi M., Gutschner T.,
RA   Genovese G., Wang G.-C., Fang Z.-N., Tepper J.M., Stemke-Hale K., Tsai K.Y.,
RA   Davies M.A., Mills G.B., Chin L.;
RT   "The RAC1 P29S hotspot mutation in melanoma confers resistance to
RT   pharmacological inhibition of RAF.";
RL   Cancer Res. 74:4845-4852(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//